1 / 25

PPI-RELATED SIBO: CLINICAL SIGNIFICANCE AND RISK FACTORS

Study on long-term PPI treatment & SIBO prevalence, risk factors, clinical manifestations, & eradication. Evaluation methods, symptoms, treatment outcomes, and statistical analysis discussed.

schotta
Télécharger la présentation

PPI-RELATED SIBO: CLINICAL SIGNIFICANCE AND RISK FACTORS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PPI-RELATED SIBO: CLINICAL SIGNIFICANCE AND RISK FACTORS Lucio LOMBARDO Monica FOTI, Olga RUGGIA Dept. Gastroenterology Mauriziano Hospital, Turin Italy DDW- AGA 2009

  2. Antisecretory medications increasebacterial count in gastric (1) and in duodenal fluids (2, 3) PPI use is associated with SIBOrecurrence after eradication with antibiotics (4) Presence of diarrhea in the elderely is positively associated with administration (among other drugs) of PPI(5) Background 1) Sanduleanu et al, Aliment Pharmacol Therap 2001; 2) Thorens et al, Gut, 1996; 3) Fried et al, Gut, 1994; 4) Lauritano et al, Am J Gastro, 2008; 5) Pilotto et al, Am J Gastro, 2008

  3. Aims of the study To determine, in patients on long-term PPI treatment: • SIBO prevalence by glucose H2 breath test (HBT) • Risk factor for development of PPI-related SIBO • Clinical manifestations of PPI-related SIBO • Eradication of SIBO after Rifaximin

  4. Evaluation of SIBO Aspiration and culture of duodenal-jejunalfluid gold standard (1). Hydrogen breath test: indirect (metabolic) evidence of bacteria • Non Invasive • Repeatible • Sensible • Specific It measures bacterial load It identifies bacterial species, but • Cumbersome • Invasive • Low reproducibility • Low sensitivity 1) Lin, JAMA 2004

  5. 200 IBS (Rome III criteria) Subtype: Diarrhea 40%, Constipation 40%, Mixed 20%) Age, meanS.D.: 37±19, M/F:102/98 Studied population • 200 patients on PPI for GERD treatment • Eso 35%, Lan 30%, Ome 15%, Rabe 10%, Panto 10%, • PPI duration: medn 36 months (range: 2 months 7 years at standard dosage) • 68% Hp- • Age, meanS.D.: 39 ± 18; M/F:120/80 • 50 Healthy controls • Age, meanS.D.: 35±16, M/F:29/21

  6. Patients: Age: 18- 75 On PPI > 2 months IBS Controls: Age : 18-75 Rome III criteria No PPI for at least 3 years Healthy Controls: Age: 18-75 N0 PPI for at last 10 years Main inclusion Criteria

  7. History of neoplasia, malabsorptions, GI surgery, metabolic or hormonal disease Use of antibiotics in the last 6 months Use of eukinetic laxatives, history of colonscopy or X-ray barium enema in the last month Main exclusion Criteria

  8. Glucose H2Breath Test Instrument: E.C.60 Gastrolyzer 50 g Glucose in 250mL Breath sampling: every 15’ until 120’ Accuracy: ± 2% of Reading Sensor Sensitivity 1 ppm Positivity criteria: increase >10 ppm in the first 120’ Gasbarrini Aliment Pharmacol Therap, 2009

  9. Evaluation of 5 symptoms by a 3-point scale (0-3) Pain Severity Pain Duration Pain Frequency Bloating Constipation / Diarrhea severity Symptom Index (S.I.) • Symptom index calculating the sum of the above symptoms score • Mild / no symptoms: 0-5 • Moderate: 6-10 • Severe: 11-15

  10. SIBO-positive were treated with the non-absorbable antibiotic Rifaximin 400 mg t.i.d. (1,200 mg) for 2 weeks. PPI treatment was continued SIBO treatment • Assessment of SIBO eradication by GHBT 2 months after completion of treatment

  11. SPSS software version 12 for W Mann-Whitney test X2 test with Yate’s correction Statistics

  12. Glucose-HBT Positivity PPI vs IBS : p< 0.001 OR 3.14 PPI vs HC: p <0.001 OR 16.0

  13. Age Distribution in PPI and IBS G-HBT positive patients

  14. Prevalence of SIBO / Duration of PPI treatment 2-12 Mo vs >13 Mo : p < 0.001, OR: 11

  15. SIBO Symptom Severity / Duration of PPI treatment

  16. Type of symptoms in SIBO patients

  17. SIBO eradication rate following Rifaximin 1,200 mg/day for 14 days P : NS

  18. SIBO eradication according to PPI treatment duration P : NS

  19. Safety • Tolerability of Rifaximin was excellent with only a 2% of minor side-effects (headache, nausea of mild grade, with prompt remission after cessation of treatment).

  20. Conclusions 1 PPI – Related SIBO • SIBO is more frequent in patients on long-term PPI treatment than in IBS patients and healthy controls • Prevalence of PPI-related SIBO and severity of symptoms increase with duration of PPItreatment • Bloating is more frequent in PPI-related SIBO than in IBS-related SIBO

  21. Conclusions 2 ERADICATION OF PPI – Related SIBO • Satisfactory (87-91%) • More Successful in patients on PPI < 12 Months • Tolerability: excellent • Recurrence in PPI population to be evaluated

  22. CONSIDERATIONS pH 4: Most Bacteria killed in 30’ (Gut 1972,13:251) ? PPI –Tx Tailoring with 2 aims: 1)tissue repair maintenance 2) gastric pH “physiological respect”: ?PPI à la démande ?Periodical ?Less aggressive

  23. Limitations of the study • Observational transversal • Open label study design • Single PPI differentiation • Hp status on SIBO

  24. MAJOR VALUES • Long-term PPI Tx in Pts • without influencing comorbidities • IBS pts “free” from PPI use • HC “free” from PPI use • Satisfactory Eradication with Rifaximin

  25. THANK YOU !

More Related